TEL AVIV, Israel, May 7, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the first quarter of 2014 and will host a corporate update conference call on Thursday, May 15, 2014.
|
Conference Call & Webcast |
|
Thursday, May 15, 2014 @ 8:30am Eastern Time/5:30am Pacific Time |
|
Domestic: |
855-469-0611 |
|
International: |
484-756-4341 |
|
Passcode: |
43962198 |
|
Webcast: |
www.alcobra-pharma.com |
|
|
|
|
Replays |
|
|
Domestic: |
855-859-2056 |
|
International: |
404-537-3406 |
|
Passcode: |
43962198 |
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX (Metadoxine Extended Release (MG01CI)), to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder, and is enrolling patients in a Phase III study for this indication in adults. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
CONTACT: U.S. Investor Contacts:
LifeSci Advisors, LLC
Michael Rice
646-597-6979
mrice@lifesciadvisors.com
Israel Investor Contact:
Alcobra Investor Relations
Debbie Kaye
+972-72 2204661
debbie@alcobra-pharma.com
